Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients.
about
Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonistElectroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeysSalvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disordersThe downward spiral of chronic pain, prescription opioid misuse, and addiction: cognitive, affective, and neuropsychopharmacologic pathwaysAnimal models of substance abuse and addiction: implications for science, animal welfare, and societyRecent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment.30 years of dynorphins--new insights on their functions in neuropsychiatric diseasesEnkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease.Genomic convergence and network analysis approach to identify candidate genes in Alzheimer's disease.Evaluation of the agonist PET radioligand [¹¹C]GR103545 to image kappa opioid receptor in humans: kinetic model selection, test-retest reproducibility and receptor occupancy by the antagonist PF-04455242.An Improved Antagonist Radiotracer for the κ-Opioid Receptor: Synthesis and Characterization of (11)C-LY2459989.Synthesis and in vivo brain distribution of carbon-11-labeled δ-opioid receptor agonists.Kinetic modeling of (11)C-LY2795050, a novel antagonist radiotracer for PET imaging of the kappa opioid receptor in humans.Test-retest reproducibility of binding parameters in humans with 11C-LY2795050, an antagonist PET radiotracer for the κ opioid receptor.Cysteine 27 variant of the delta-opioid receptor affects amyloid precursor protein processing through altered endocytic trafficking.Chromatin alterations in response to forced swimming underlie increased prodynorphin transcriptionElevated OPRD1 promoter methylation in Alzheimer's disease patients.Pharmacological traits of delta opioid receptors: pitfalls or opportunities?Synthesis of a potent and selective (18)F-labeled delta-opioid receptor antagonist derived from the Dmt-Tic pharmacophore for positron emission tomography imaging.Synthesis and evaluation of 11C-LY2795050 as a κ-opioid receptor antagonist radiotracer for PET imagingDetermination of in vivo Bmax and Kd for 11C-GR103545, an agonist PET tracer for κ-opioid receptors: a study in nonhuman primatesNeurocognitive and neuroinflammatory correlates of PDYN and OPRK1 mRNA expression in the anterior cingulate in postmortem brain of HIV-infected subjects.Opioid system functional regulation in neurological disease management.The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.Opioid system and Alzheimer's disease.The Opioid System in Temporal Lobe Epilepsy: Functional Role and Therapeutic Potential.Discriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions.OPRD1 Genetic Variation and Human Disease.Decreased [3H]naloxone Binding in the Dentate Gyrus of Cloninger Type 1 Anxiety-Prone Alcoholics: A Postmortem Whole-Hemisphere Autoradiography Study.A GPCR/secretase complex regulates beta- and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis.Low μ-Opioid Receptor Status in Alcohol Dependence Identified by Combined Positron Emission Tomography and Post-Mortem Brain Analysis.
P2860
Q24535736-F68D6293-3AE9-4495-95D3-1D8C93A87EB8Q24681053-F7748C06-1BB0-4C09-8D39-3E1528DBE35FQ26781580-E7CD2FEC-A137-4647-881B-2D335FEAF261Q26824011-3D0864C1-FCB3-4E2C-852F-6C7F7B10FA64Q30433958-2E9CB9BF-FAF7-4FC8-97A8-6DD16D489D87Q30442231-6363C084-7399-4556-AC50-87E98A03108EQ30481450-8EB9BE61-1445-4F81-9B2F-61639863C591Q30512265-AA08DB4A-7ACB-420B-BAC0-0E31433FA92AQ33637672-D50BB7C6-D7AB-452D-8280-854F3D671428Q34073200-7F454275-FD58-485F-8EEC-355C8216A2EBQ34421107-A75DF72A-7892-4415-8C4A-51C93BD5D292Q34476749-881AD6FD-B83F-45C2-9770-D068078B5DEBQ34727498-B99BEBD9-9A98-433E-8E21-59CDF8215E38Q35067118-5D76A5F4-5248-4FC4-A6F1-32B48179A247Q35096287-F1FF9863-58B0-4022-899B-F599E24B3A40Q36143981-11B17AED-1578-4D0B-8C30-346210064C0CQ36295228-E2CF7D86-AC52-439D-B77E-C3C04465D20AQ36920342-7D8A22ED-F294-4745-AED6-1DAA9B0F5887Q37153933-D6DCA131-CC0B-4407-BE28-37E29CC532B9Q37177752-5AFC296C-E093-4A18-9C7B-8484ED911122Q37177769-3FFA8B2D-FE03-45A3-92AA-BDB77885854BQ37496856-65D60D45-3FE2-44AC-BD95-309FB7B22BBCQ37782045-EB7CEB4A-53D1-46EB-9CB9-77CECACCAD51Q37946259-E96BA771-1904-4B62-A704-250197BE9CD1Q38004941-04EF8C25-3904-4AF5-AA76-BB3287CA8AECQ38616839-A8F55451-FA26-45B2-AEC0-5367481D480EQ38862468-A2C4242E-DEAD-45B1-95BA-FFC9081EAEBEQ39051440-38C5C92E-649A-4359-9121-78AD662355B5Q41610569-B868E550-EC36-40F4-803D-A396E0DA6E3AQ43197086-17F17578-F81A-4FDE-8315-3160D8286F98Q44339317-1F55FCE4-5C12-4BC6-9FDC-D5BB2B6C4566
P2860
Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Mu-, delta- and kappa-opioid r ...... Alzheimer's disease patients.
@ast
Mu-, delta- and kappa-opioid r ...... Alzheimer's disease patients.
@en
type
label
Mu-, delta- and kappa-opioid r ...... Alzheimer's disease patients.
@ast
Mu-, delta- and kappa-opioid r ...... Alzheimer's disease patients.
@en
prefLabel
Mu-, delta- and kappa-opioid r ...... Alzheimer's disease patients.
@ast
Mu-, delta- and kappa-opioid r ...... Alzheimer's disease patients.
@en
P2093
P1433
P1476
Mu-, delta- and kappa-opioid r ...... Alzheimer's disease patients.
@en
P2093
P304
P356
10.1016/S0006-8993(00)03302-3
P407
P577
2001-03-01T00:00:00Z